explore -WSS

explore

author：comprehensive 2025-09-02 13:50:40 - browse：1596

Adobe

The medical device industry is split on whether a proposed new Medicare reimbursement pathway will do anything to soothe their insurance coverage woes.

Device makers have long complained that the unclear, rocky road to payment kills innovative companies. So they were thrilled when the Trump administration proposed a rule that would have guaranteed four years of Medicare coverage of approved devices deemed “breakthroughs” by the Food and Drug Administration. They hoped private payers would follow suit. But in 2021, under a new administration and a push for more device scrutiny, the Centers for Medicare and Medicaid pulled back on the idea, promising a replacement that would streamline coverage for innovative devices while ensuring safe, high-quality care.

The pathway put forth last week, called Transitional Coverage for Emerging Technologies (TCET), is only a notice, not yet a rule that would grant CMS new powers. The program applies solely to devices that have earned a place in the FDA’s breakthrough device program, which was established to identify devices that the agency believed could provide “more effective” treatment or diagnosis of serious conditions than the current standard of care. But because those devices can be brought to market with less certainty in their benefits and risks than other products, experts said, the idea of automatic reimbursement was dicey.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Colonoscopy prep: Liquid

Wikipedia

focus

WSS

Plastic surgeons increase patient psychiatric screenings

Argenx readies a blockbuster opportunity with drug for autoimmune disease

The EU Joint Clinical Assessment needs to live up to its promise

Solve the antibiotic resistance crisis with preventive drugs

Argenx readies a blockbuster opportunity with drug for autoimmune disease

NIH confirmation hearing shows politicization of research

leisure time

explore

hotspot

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

STAT Summit: Biotech founders on deal

Medical leaders decry Supreme Court decision on affirmative action

How climate

Guidelines to prevent youth baseball injuries need more muscle

Neuroscience’s long legacy of racism

Cancer drug shortages should be causing more outrage

HHS leader on health, climate change and biopharma emissions

Cancer drug shortages should be causing more outrage

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

hotspot

Positive childhood experiences can help future health

NIH confirmation hearing shows politicization of research

FDA struggles to regulate food additives, sometimes for decades

App could help diagnose ear infections more accurately — and at home

STAT Summit: Biotech founders on deal

Readout Newsletter: Bluebird, CVS, Contineum

Wikipedia

focus

hotspot

leisure time